First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

Investigational New Drugs

Volumn 35, Issue 3, 2017, Pages 315-323

  Shapiro, Geoffrey I ^a   Vaishampayan, Ulka N ^b   LoRusso, Patricia ^c   Barton, Jeremy ^d   Hua, Steven ^d   Reich, Steven D ^d   Shazer, Ronald ^d   Taylor, Carrie T ^d   Xuan, Dawei ^d   Borghaei, Hossein ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY   (United States)

^d PFIZER INC   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

5T4; Antibody drug conjugate; Immunoconjugate; Monomethylauristatin conjugate; PF 06263507; Solid tumors

Indexed keywords

5T4 ANTIGEN; ANTIBODY DRUG CONJUGATE; PF 06263507; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VEDOTIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOMETHYLAURISTATIN F; OLIGOPEPTIDE; TROPHOBLASTIC GLYCOPROTEIN 5T4, HUMAN;

ADENOID CYSTIC CARCINOMA; ADENOMA; ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BLURRED VISION; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONJUNCTIVITIS; DECREASED APPETITE; DEVICE INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRY EYE; DYSGEUSIA; EMBOLISM; ESOPHAGUS CANCER; EYE PAIN; FATIGUE; FEMALE; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPERCALCEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOGENICITY; INFLAMMATION; KERATITIS; KIDNEY CARCINOMA; LACRIMATION DISORDER; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; SENSORY NEUROPATHY; SOLID MALIGNANT NEOPLASM; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VERY ELDERLY; VITREOUS FLOATERS; VOLUME OF DISTRIBUTION; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; METABOLISM; NEOPLASM; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; KERATITIS; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASMS; OLIGOPEPTIDES; PHOTOPHOBIA; TREATMENT OUTCOME;

EID: 85008712555     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0419-7     Document Type: Article

References (30)

1. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14:529–537
2. Sapra P, Hooper AT, O’Donnell CJ et al (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 20:1131–1149
3. Boghaert ER, Sridharan L, Khandke KM et al (2008) The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol 32:221–234
4. Hole N, Stern PL (1990) Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer 45:179–184
5. Hole N, Stern PL (1988) A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 57:239–246
6. Southall PJ, Boxer GM, Bagshawe KD et al (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89–95
7. Damelin M, Geles KG, Follettie MT et al (2011) Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 71:4236–4246
8. Al-Taei S, Salimu J, Lester JF et al (2012) Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer 77:312–318
9. Starzynska T, Marsh PJ, Schofield PF et al (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899–902
10. Wrigley E, McGown AT, Rennison J et al (1995) 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 5:269–274
11. Naganuma H, Kono K, Mori Y et al (2002) Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 22:1033–1038
12. Castro FV, McGinn OJ, Krishnan S et al (2012) 5T4 oncofoetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. Leukemia 26:1487–1498
13. Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–124
14. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PY (2006) Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 5:1474–1482
15. Sapra P, Damelin M, Dijoseph J et al (2013) Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 12:38–47
16. Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 4:1149–1161
17. O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method. A practical design for phase 1 clinical trials in cancer. Biometrics 46:33–48
18. U.S. Department of Health and Human Services, National Cancer Institute. CTCAE v4.03. NIH Publication No. 09–5410, revised June 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 6 Sept 2016
19. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
20. Tannir NM, Forero-Torres A, Ramchandren R et al (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs 32:1246–1257
21. Moskowitz CH, Forero-Torres A, Shah BD et al (2014) Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma. Blood 124:1741–1748
22. Fathi AT, Chen R, Trippett TM et al (2014) Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood 124:963–969
23. Eaton JS, Miller PE, Mannis MJ et al (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31:589–604
24. Moore KN, Martin LP, Matulonis UA et al (2016) IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). J Clin Oncol 34 (suppl; abstr 5567)
25. Rudin CM, Pietanza MC, Bauer TM et al (2016) Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol 34 (suppl; abstr LBA8505)
26. Shor B, Kahler J, Dougher M et al (2016) Enhanced antitumor activity of an anti-5T4 antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes. Clin Cancer Res 22:383–394
27. Shapiro G, Bell-McGuinn K, Molina J et al (2015) First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res 21:1888–1895
28. Del Campo JM, Birrer M, Davis C et al (2016) A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol 142:62–69
29. Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32:3494–3507
30. Tian F, Lu Y, Manibusan A et al (2014) A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A 111:1766–1771